INTRODUCTION
The vasodilator peptide AM (adrenomedullin) was discovered in phaeochromocytoma cell extracts by its ability to initiate cAMP production in target cells [1] . AM is now considered as a paracrine factor associated with states of cellular growth and is expressed in various human malignancies [2] . AM is stimulated by hypoxia [3] under control of the basic helix-loop-helix transcription factor type, display biallelic loss-of-function mutations in the tumour-suppressor gene VHL (von Hippel-Lindau) [5] . In the presence of oxygen, VHL is crucial for ubiquitinmediated targeting of constitutively transcribed HIF-1α to proteasomal degradation [6] . Indeed, in the vast majority of CC-RCCs with VHL mutations, HIF-1α mRNA level is not changed, whereas HIF-1α protein is elevated significantly [7] . In these tumours, there is a close correlation between the level of HIF-1α protein and HIFtarget gene products, e.g. VEGF (vascular endothelial growth factor) [7] .
Based on these findings, we hypothesized that AM would be constitutively up-regulated in solid kidney tumours of clear cell type. The hypothesis was tested in human tumour tissue from nephrectomy samples. CC-RCC is an obvious target for better approaches for early detection of disease. AM is not stored in cells, but constitutively released at a rate that reflects transcription and translation. Since AM is expected to be elevated constitutively in all tumour cells in CC-RCC, we speculated that AM could be a potential serum marker for CC-RCC compared with other histological types of human renal and non-renal cancer. In the present study, we validated commercial immunoassays for the detection of AM in plasma and applied them to plasma samples from patients. Measurements were done in consecutive preand post-surgery samples of blood plasma from patients with CC-RCC and other renal neoplastic and nonneoplastic diseases.
MATERIALS AND METHODS

Subjects and design of study
The study was approved by the Institutional Review Board Ethical Committee (approval no. 20010035). All patients gave informed written consent for the use of tissue from the extirpated kidney and collection of blood samples. All samples in this study were obtained from randomly selected patients who underwent unilateral total nephrectomy for renal cancer at the Department of Urology, Odense University Hospital, Odense, Denmark. Blood samples were also obtained from six patients who underwent nephrectomy for reasons other than malignant disease. The pathological profiles of the patients who participated with consecutive blood samples are shown in Table 1 . Before the blood sampling protocol began, several other patients donated nephrectomy specimens.
Collection of human blood and renal tissue samples
Antecubital venous blood was collected into cooled vacuum tubes containing EDTA and transferred to tubes with aprotinin. The samples were then centrifuged at 1500 g for 15 min at 4
• C, and separated plasma was stored at − 80 • C until assay. The first blood sample was obtained on the morning of surgery, the second was taken 3-6 days after surgery, and the third was collected 4-5 weeks after surgery. Immediately after removal, the kidney was transported to the Department of Pathology. A nephropathologist excised a portion of the tumour and normal tissue from the same kidney. Normal tissue was only collected from specimens where a segment of normal tissue, including both cortex and an intact papilla, was present. The normal tissue was dissected to give cortex and medulla. All tissue samples were frozen in liquid nitrogen and stored at − 80
• C. For histological analysis, a tissue block of the border zone between the tumour and non-malignant kidney was fixed in 4 % formaldehyde for 24 h and then embedded in paraffin. Tumours were diagnosed and classified according to the WHO (World Health Organization) classification [8] .
Extraction of RNA and protein from tumour and normal kidney tissue
Total RNA was extracted from tumours and adjacent non-malignant renal cortex by using the RNeasy Midi Kit (Qiagen). Protein was isolated by homogenization of 200-250 mg of tissue in lysis buffer [1 mM Tris/HCl, 10 mM EDTA and 1 mM DTT with a protease inhibitor mix (Complete Protease Inhibitor; Roche Diagnostics) at pH 7.2]. Subsequently, 10 µl of Triton X-100 [10 % (w/v) final concentration] was added followed by centrifugation at 11 000 g at 4
• C for 10 min. The supernatant was removed and centrifuged again at 11 000 g at 4
• C for 10 min. Protein concentration was measured using a BioRad Laboratories protein assay. Duplicate samples were diluted and compared with a BSA standard curve using spectrophotometry (Cary 50 Scan; Merck). Aliquots were stored at − 80
• C.
RT-PCR (reverse transcription-PCR) and cloning of PCR products
Human kidney RNA and CC-RCC RNA (1 µg) was reverse transcribed, and 50 ng of cDNA was used as a template for amplification by PCR as described previously [9] . The following DNA oligonucleotides (Invitrogen) were used for amplification: 5 -TCCGAAACCATGAA-CTTT-3 (sense) and 5 -TCCACCAGGGTCTCGATT-3 (antisense) for VEGF, covering bases 693-880 (188 bp; Genbank ® accession no. NM 003376); and 5 -ACCG-ATTCACCATGGAGG-3 (sense), and 5 -TCCAAA-TCACCAGCATCC-3 (antisense) for HIF1-α, covering bases 254-500 (257 bp; Genbank ® accession no. NM 001530). Primers were synthesized with restriction sites in the 5 direction for BamHI (sense) and EcoRI (antisense). PCR products were subcloned in plasmid pSP73 (Promega) and sequenced as described previously [9] . A fragment of human AM cDNA (310 bp) has been cloned and sequenced previously [10] . 
RPA (ribonuclease protection assay) for AM, VEGF and HIF-1α mRNAs
The RPA was performed as described previously [9] . In addition to AM, VEGF mRNA was determined as a positive control for CC-RCC [7] . HIF-1α is stable at the mRNA level in malignant tissue and normal kidney cortex and it was used as a control for RNA quality and loading [7] . Initial experiments were done to assure surplus of probes and to elucidate the linear range of assays and feasibility of detecting all three mRNAs in one sample. RNA samples from 28 patients could be analysed simultaneously on one gel. RNA from matched samples of tumour and non-malignant renal cortex from one patient was always analysed on the same gel, each in duplicate. Thus four wells were occupied by RNA from one patient, and seven different patients were analysed in each assay. The duplicates consisted of 10 and 20 µg or, when possible, 20 and 40 µg of total RNA. By using this design it was possible to calculate the fold change of the relevant mRNA in the tumour compared with the adjacent cortex for each patient and thereby compare different assays. Protected probes were separated by urea/ PAGE for 2 h and quantified as described previously [9] .
Extraction of plasma
Because of the reported inaccuracy and poor validity of commercial assays for AM [11, 12] , we validated two commercial assays for detection of human AM in plasma: (i) an RIA involving a plasma extraction procedure (DRG Diagnostics), and (ii) an IRMA (immunoradiometric assay) with no plasma extraction (Shionogi) [13] . For the RIA, plasma was extracted using several extraction procedures: extraction 1, which is used routinely in our laboratory; extraction 2, as described by the manufacturer (DRG Diagnostics); and extractions 3a and 3b, which have been used by others previously to detect AM [11] . Plasma samples were prepared as described in Table 2 and applied on to conditioned Sep-Pak C 18 cartridges. After washing the cartridges, samples were eluted using the solvents described in Table 2 . Samples were collected in tubes containing Triton X-100 and evaporated to dryness under a stream of air in a 25
• C water bath overnight.
Immunoassays for AM
The RIA developed by DRG Diagnostics has a reported detection range of 1-128 pg/tube (approx. Table 2 Extraction of plasma samples for use in the DRG Diagnostics RIA for AM PATC buffer, 0.05 mol/l phosphate buffer (pH 7.4) with 1 g/l ATC (alkali treated casein), 1 ml/l Triton X-100, 0.1 g/l sodium EDTA and 0.2 g/l sodium azide. ATC was made by adding 5 g of casein to 20 ml of water, followed by 25 ml of 2 M NaOH and 100 µl of 10 M H 2 O 2 . The solution was left overnight at room temperature. After filtration (Whatman 541), the pH was adjusted with 1 M acetic acid to 7-8 and filtration was repeated using a Whatman GF/A filter. The pH was lowered to 4.5-4.6 with 1 M acetic acid. After 30 min, the supernatant was discarded, the precipitate washed with water, dissolved in aqueous ammonia and vacuum dried. The composition of PBSA buffer was as for PATC buffer, but with 5 g/l BSA (Sigma) instead of ATC. TFA, trifluoroacetic acid.
Extraction protocols
Conditioning of Sep-Pak 6 ml of 4 % acetic acid in 6 ml of 4 % acetic acid in 6 ml of 100 % methanol 6 ml of 100 % methanol C 18 cartridges 96 % methanol and 6 ml of 96 % methanol and 6 ml of 100 % methanol 100 % methanol Equilibration 6 ml of water 6 ml of water 6 ml of water 6 ml of water Sample preparation 1 ml of sample was added 1 ml of sample was added 1 ml of sample was added 1 ml of sample was added to 3 ml of 4 % acetic acid to 2 ml of 1 % TFA to 1 ml of PATC buffer to 1 ml of PBSA buffer with 0.1 % TFA Washing 6 ml of Mili-Q water 2 ml of 1 % TFA 6 ml of saline (9 g/l NaCl) 6 ml of saline (9 g/l NaCl) Elution 3 ml of 4 % acetic acid in 2 ml of 60 % acetonitrile 3 ml of 80 % isopropanol 3 ml of 80 % isopropanol 80 % methanol with 0.1% TFA in 1 % TFA with 0.013 ml/l HCl with 0.013 ml/l HCl Collection 10 µl of 0.1 % Triton X-100 10 µl of 0.1 % Triton X-100 10 µl of 1 % Triton X-100 10 µl of 1 % Triton X-100 0.17-21 fmol/tube; molecular mass of AM is 6029 g/mol) and uses a polyclonal antibody which does not discriminate between active mAM (mature AM) and the intermediate-inactive form AM-Gly (glycine-extended AM) [13] . The IRMA developed by Shionogi measures total AM (mAM + AM-Gly) and uses two monoclonal antibodies against different regions of human AM. The assay has a detection range of 2-500 fmol/ml and does not require extraction of plasma. All procedures were conducted according to the manufacturer's instructions. Final samples in both kits were counted in a γ -counter (Cobra; Packard).
Assay characteristics
Plasma extraction protocols were evaluated by measuring recovery and precision by within-assay and betweenassay CVs (coefficients of variation). Accuracy was determined by measuring linearity of serially diluted plasma samples. Recovery was determined by adding 45.5 fmol/ ml (Shionogi) or 49.8 fmol/ml (Phoenix Pharmaceuticals) exogenous AM to a plasma sample from a healthy human volunteer. Recovery of radioactive label was measured by applying 10 200 c.p.m. of 125 I-labelled AM to the Sep-Pak C 18 cartridges.
Immunohistochemistry
Tumour tissue was fixed in 4 % formaldehyde at 4
• C for at least 24 h, dehydrated and embedded in paraffin by standard procedures. Sections (4 µm thick) were mounted on glass slides. All sections were stained under the same conditions with a specific anti-AM antibody (H-010-01; Phoenix Pharmaceuticals) as described previously [10] . Staining for HIF-1α was done basically as described previously [7] using an anti-(human HIF-1α) antibody (NB 100-123; Novus Biologicals) at a dilution of 1:1000. Antigen retrieval was done by pressurecooking for 10 min with target retrieval solution (S1599; DAKO) and the Catalyzed Signal Amplification System (DAKO). Light counterstain with haematoxylin was used. Negative controls were performed using 5 % (w/v) dry milk and non-immune mouse IgG for amplification. Two investigators independently evaluated the labelled sections in a blinded fashion. We used the method described by Zhong et al. [14] to score the tumour sections as follows: −, no staining, + nuclear staining in less than 1 % of cells, ++, nuclear staining in 1-10 % of cells, +++ nuclear staining in 11-50 % of cells and ++++, nuclear staining in > 50 % of cells. When scoring of a sample differed, the section was re-evaluated by both reviewers simultaneously. Sections were inspected in a BX51 Olympus microscope.
Statistics and data presentation
Data obtained for mRNA expression and peptide concentration in paired samples of tumour and normal cortex were evaluated using one-sample Student's t test on the average tumour/cortex ratio. The null hypothesis was that there was no difference between cortex and tumour in which case the hypothetical ratio would be 1. Data obtained by consecutive plasma sampling in the same patient were evaluated by Student's t test for paired observations. When two independent groups were compared (e.g. healthy controls and patients with malignant kidney disease) Student's t test was used to evaluate the level of statistical significance. P < 0.05 was considered significant. Values are expressed as means + − S.E.M.
RESULTS
Patient characteristics
A total of 25 patients were examined by three consecutive blood samples before and after nephrectomy, 19 of whom had malignant kidney disease (Table 1) . Plasma creatinine was within the normal range before surgery (98.5 + − 3.5 µmol/l) and increased significantly 2-3 days after nephrectomy when data from all patients were pooled (114.5 + − 4.8 µmol/l, n = 20; P < 0.02, as determined by a paired Student t test). Renography was done in all patients before surgery and showed that, in patients with malignant renal disease, the kidneys did not display similar function (Table 1 ; n = 18; P < 0.01, as determined by a paired Student t test). The affected kidney in each case had the lower performance. In six patients who underwent nephrectomy for non-malignant indications, this difference was more pronounced (Table 1 ; P < 0.001, as determined by a paired Student t test). There was no significant difference in blood pressure between patients with CC-RCC and non-CC-RCC (mean systolic pressure, 153 + − 7 compared with 152 + − 8 mmHg; mean diastolic pressure, 90 + − 8 compared with 85 + − 4 mmHg), but patients with neoplastic disease exhibited significant (P < 0.02) systolic hypertension compared with the patients without neoplastic renal disease (mean systolic pressure, 152 + − 5 compared with 128 + − 8 mmHg; mean diastolic pressure, 87 + − 3 compared with 80 + − 6 mmHg).
AM, HIF-1α and VEGF mRNA expression in homogenates of human renal tumours and adjacent cortex tissue
Cloned cDNAs matched the published sequences by between 96 and 100 %. There was a linear relationship between the quantity of total RNA assayed (5-40 µg) and protected radioactivity in all three hybridization products, both when one probe was applied in one RNA sample and when all three probes were added simultaneously in one sample (Figure 1 ). This indicates that the probe was present in excess. Hybridization products displayed the expected molecular size and, in the absence of template RNA, probes were completely digested whereas, in the absence of RNAse, probes remained intact (Figure 1 ). In CC-RCC patients, average AM mRNA ratio between the tumour and adjacent non-malignant renal cortex was significantly higher than 1 (P < 0.02, as determined by a paired Student t test) (Figure 2 ). Of note, in four of the 18 CC-RCCs analysed, the AM ratio was at or below 1.5, indicating no significant difference. In non-CC-RCC, there was no difference in AM mRNA level when the tumour tissue was compared with adjacent renal cortex (Figure 2 ). VEGF mRNA level was also increased significantly in CC-RCC compared with adjacent nonmalignant renal cortex (P < 0.001, as determined by a paired Student t test), but was not significantly different in non-CC-RCC tissue compared with adjacent renal cortex ( Figure 2 ). As shown previously [7] , HIF-1α mRNA level was similar in all samples investigated, both malignant and adjacent cortex tissues, which indicated similar quality and loading of RNA.
Validation of AM peptide assays
The RIA kit from DRG Diagnostics was applied first and different extraction procedures were tested (see Table 2 ) in an attempt to optimize the results. No meaningful results were obtained from extraction 2 (results not shown), and extractions 1 and 3 exhibited low recoveries of added AM, displaying high between-assay and intraassay variation and non-linear dilution curves with low accuracy (Table 3) . Thus, despite continuous dilution, AM was detected at similar concentrations. Recovery of radiolabelled AM was comparably better, which indicated that the extraction procedure was effective, but that downstream assay detection was not quantitative. The assay was therefore not used subsequently. The IRMA kit (Shionogi) did not require extraction and exhibited far better performance (Table 3) . Assay accuracy was demonstrated by the linearity of AM concentrations measured in serially diluted plasma samples ( Table 3 ). The assay exhibited low within-assay and between-assay CVs that corresponded to values given by the manufacturer, both with control plasma (within assay, n = 5; and between assays, n = 8) and with plasma spiked with 45.5 fmol/ml of exogenous AM (within assay, n = 5; between assays, n = 9; Table 3 ). Recovery was excellent with AM peptide obtained from Shionogi, but not from a different manufacturer (Table 3) . Assay validity for tissue homogenates was tested. Posthomogenization recovery was between 33.7 and 46.7 %, but pre-homogenization recovery was only found to be between 5.7 and 7.9 %. Between-and within-assay CVs were not measured for the tissue homogenates because of limited tissue availability.
AM peptide content in homogenates of renal tumour tissue and adjacent renal cortex
AM peptide concentration was determined by IRMA in tissue homogenates and normalized for protein concentration. There was no difference in AM content between normal adjacent cortices from kidneys with CC-RCC and non-CC-RCC and, therefore, the values were pooled. There was a significantly higher (P < 0.02, as determined by an unpaired Student t test) AM concentration in homogenates from CC-RCC (1.82 + − 0.3 fmol/mg of protein; n = 13) compared with non-malignant renal cortex (0.41 + − 0.06 fmol/mg of protein; n = 17). There was no significant difference in AM concentration between non-malignant cortex (0.41 + − 0.06 fmol/mg of protein; n = 17) and non-CC-RCC (0.55 + − 0.09 fmol/mg of protein; n = 6) homogenates. In a number of cortex samples, the AM concentration was below the detection limit of the assay while AM in the tumour was detectable. In those paired tissue homogenates where AM could be detected both in cortex and tumour, the tumour/cortex AM concentration ratio was calculated. The AM ratio was significantly higher (P < 0.006, as determined by an unpaired Student t test) than 1 in CC-RCC (5.50 + − 1.07; n = 9) but not in non-CC-RCC (1.67 + − 0.28; n = 5).
Pre-and post-nephrectomy plasma concentration of AM in patients with renal tumours
Average plasma concentration of total AM (AMGly + mAM) in eight healthy human control individuals (four male and four female; median age, 37 years) was 8.14 + − 0.72 (range, 5.37-11.20) fmol/ml. Before nephrectomy, there was no difference between total plasma AM concentration in patients with CC-RCC (median age, 69 years; n = 9) compared with patients with a renal tumour of a different histological classification (median age, 65 years; n = 10) (Figure 3 ). Pre-surgery plasma AM concentration in all patients with malignant renal tumours was 12.8 + − 0.9 fmol/ml (n = 20), which was significantly higher (P 0.004, as determined by an unpaired Student t test) than in healthy control individuals. At 3-6 days after surgery, there was a significant increase in plasma AM level in both groups of tumour patients (P < 0.05 and P < 0.005 in CC-RRC and non-CC-RCC respectively, as determined by paired Student t tests; Figure 3 ). After 4-5 weeks, plasma AM concentration was not statistically different from the pre-surgery level in the nephrectomized patients (Figure 3) .
We measured plasma AM in six patients who underwent unilateral nephrectomy for indications other than malignant kidney disease (median age, 48 years; Table 1 ). The pre-surgery AM concentration was 15.6 + − 3.1 fmol/ml, which was significantly higher (P 0.02, as determined by an unpaired Student t test) than in healthy controls. At 3-6 days after surgery, plasma AM was 24.1 + − 3.9 fmol/ml and, after 4-5 weeks, the level was 15.9 + − 1.9 fmol/ml. These values were not significantly different from pre-surgery plasma AM levels (as determined by a paired Student t test). Values are means + − S.E.M. There was no significant difference between plasma AM levels in patients with CC-RCC compared with patients with non-CC-RCC. Plasma AM increased significantly in both groups of patients 3-5 days after surgery ( * P < 0.05 for CC-RCC; * P < 0.005 for non-CC-RCC). At 4-5 weeks after nephrectomy, plasma AM had returned to pre-surgery levels.
Immunohistochemical labelling of renal tumour tissue for AM and HIF-1α
A series of renal tumour samples were labelled for AM by immunohistochemistry (CC-RCC, n = 25, papillary RCC, n = 1; urothelial carcinoma, n = 3; angiomyolipomas, n = 2; oncocytoma n = 2; Figure 4 ). No obvious differences in staining intensity were found between the different tumour types. Thus AM was detected in the cytoplasm of tumour cells in the vast majority of CC-RCC samples, whereas little if any staining was associated with the stroma ( Figure 4A ). Most non-CC-RCC samples also displayed a variable degree of AM-positive tumour cells. Of note, AM-labelled tumour cells were homogeneously distributed in CC-RCC tissue ( Figure 4A and 4B). In the adjacent non-malignant renal tissue, AM was associated with distal tubules (Figure 4C ) and collecting ducts regardless of the type of malignancy. In the absence of the primary anti-AM antibody, no labelling was detected ( Figure 4D ). Randomly selected CC-RCCs (n = 17) and non-CCRCCs (n = 12) were stained for HIF-1α in order to ascertain the correct diagnosis of CC-RCCs and to compare the pattern of distribution with non-CC-RCCs. Normal kidney tissue displayed very little staining for HIF-1α and, in several samples, no signals were detectable ( Figure 5D ). In some cases HIF-1α-immunoreactive protein was observed in normal tissue adjacent to the invading tumour ( Figure 5F ). In complete contrast with normal kidney tissue, 13 out of 17 (76 %) of CCRCCs exhibited homogeneous strong labelling (+++ and ++++) that was associated with tumour cell nuclei ( Figures 5A and 5B) . In CC-RCC, localization of HIF-1α-positive cells did not depend on position within the tumour, e.g. at margins, in cysts or close to vessels ( Figures 5A and 5B) . Incubation with non-specific mouse IgG or omission of primary anti-HIF antibody did not result in labelling of CC-RCC, despite the use of signal amplification ( Figure 5C ). Immunostaining for HIF-1α in tumours diagnosed as non-CC-RCC was heterogenous and sparse ( Figures 5E-G) . HIF-1α labelling was associated with cell nuclei that typically accumulated at sites associated with necrosis or inflammatory cell infiltrates ( Figure 5E ) or at the invading margin ( Figure 5F ; transitional RCC). In renal papillary tumours, HIF labelling was typically associated with single cells in the wall of intratumoral cysts, whereas the bulk of tumour cells were negative ( Figure 5G ). Non-CC-RCCs received low scores (all were + and ++), indicating that the estimated number of HIF-positive nuclei was < 10 % in all 12 samples investigated. 
DISCUSSION
In the present study we tested the hypotheses that the vasodilator peptide AM is constitutively elevated in CC-RCC tissue and that AM is a plasma marker for CC-RCC. The data have shown that AM mRNA and protein were significantly and selectively elevated in CCRCCs compared with adjacent renal cortical tissue. The majority (76 %) of CC-RCCs displayed strong homogeneous nuclear labelling for HIF-1α, whereas none of the examined non-CC-RCCs had this pattern of HIF-1α distribution. Plasma AM concentration was significantly increased in patients with renal malignant disease compared with a group of healthy controls. Plasma AM in patients with CC-RCC was not different from that in patients with other renal malignant tumours. Rather than the decrease in plasma AM predicted by our hypothesis, we observed that nephrectomy led to a significant increase in plasma AM concentration in all patient groups 3-6 days after surgery. Plasma AM subsequently stabilized to presurgery levels 4-5 weeks after nephrectomy.
The present findings and those published previously [11, 12] of unreliable detection of AM in plasma by immunoassays indicate that commercial assays should be subjected to rigorous validation before general use in clinical settings. Assay accuracy is vital because AM is known as a 'sticky' peptide and most reported changes in plasma AM are of a small magnitude. We found that, in our hands, the IRMA kit for total AM performed far better than the RIA and was valid and reproducible on all criteria tested. We are not aware of previous studies on plasma AM concentrations in renal cancer patients. Plasma AM is elevated in patients with lung cancer and gastrointestinal cancers [15] , whereas it is not different from controls in patients with breast cancer [16] . Because localized hypoxia is an inherent property of most solid tumours, it is not surprising that plasma AM is elevated in many common cancer types. We observed that plasma AM was also elevated in six patients admitted for nephrectomy but without malignant disease. A common denominator for the patients that underwent nephrectomy was impaired function of the affected kidney, as indicated by renography. Renal impairment is associated with increased plasma AM concentration [17] , but judging from plasma creatinine concentration overall renal function was not affected differently in the patients. At 4-5 weeks after nephrectomy, plasma AM was still significantly higher than in healthy controls. This indicates that the elevated AM level is not related to the diseased kidney. Systolic blood pressure was significantly higher in patients with renal cancer compared with patients admitted for nephrectomy without neoplastic disease, but AM was elevated equally in both groups. It is not clear what the mechanism is that underlies elevated plasma AM in the group of nephrectomized patients.
Most sporadic CC-RCCs (50-70 %) exhibit mutations in the tumour suppressor gene VHL [5, 7] . We did not perform mutational analysis for VHL in the present study, but relied on classical pathological criteria. The tissue and plasma measurements of AM showed very little variation. Thus it is unlikely that a subgroup of patients diagnosed as 'clear cell' but without VHL mutations display markedly different plasma AM concentrations. In support of correct pathological diagnosis, the majority of clear cell tumours in the present study displayed uniform nuclear labelling for HIF-1α throughout the tumour and VEGF mRNA was selectively elevated in these tumours. Both features are consistent findings in CC-RCCs with VHL mutations [7, 18] . Only CC-RCCs exhibited elevated AM mRNA and peptide levels compared with normal kidney cortex. In a previous study, Fujita et al. [18] found very similar changes in AM and VEGF mRNAs in CC-RCCs by PCR analysis. Taken together, the findings support the concept that constitutively elevated HIF is crucial for increased expression of an array of hypoxia-controlled gene products, including AM, in CC-RCC with VHL mutations [7] . There are several ways that AM overexpression could affect growth of CC-RCCs. AM is a direct growth factor for certain tumour cells [19] , it inhibits apoptosis [20] and promotes angiogenesis [21] . In CC-RCC, AM correlates with vascular density and could be important for tumour angiogenesis in this highly vascularized tumour type [18] . AM is significantly expressed in normal kidney and is associated with distinct nephron segments, the collecting duct system and urothelium lining the urinary tract [10] . This indicates that renal AM expression is not only controlled by hypoxia and/or HIF and this could be one reason that non-CC-RCCs also display immunohistochemical staining for AM. AM therefore appears less suited to discriminate in an 'all or none fashion' between non-CC-RCC and CC-RCC at the level of immunohistochemistry. Only quantitative measurements of AM in tumour tissue extracts document a significant difference between CC-RCC and non-CC-RCC. The significantly higher level of AM mRNA and peptide in CC-RCC prompted us to test its use as a serum marker.
Plasma AM increased acutely after excision of the kidney and tumour. There is no clearly defined organ source of AM in plasma under normal conditions [22] . The rise in plasma AM could be related to surgical manipulation of AM-rich tumours, or the adrenal gland, or to general surgical stress. Major surgical stress has been shown to elevate plasma AM concentration strongly during the operation and in the first days after surgery [23] . For this reason, we included the second measurement of AM 4-5 weeks after surgery. After major surgery, AM stabilizes after 1 week [23] ; however, the finding that AM had not decreased significantly below pre-surgery levels after 4 weeks precludes its use as a specific marker for CC-RCC. The only condition where consecutive determinations of plasma AM have been reported to reflect the presence of a tumour is phaeochromocytoma. One study [24] reported a dramatic decrease in plasma AM after adrenalectomy, whereas no difference in plasma AM was recorded in a second study of similar patients [25] . Thus there are no well-established conditions where AM could be used as a serum marker for the presence of tumour tissue at present.
In summary, our findings show that HIF-1α and the HIF-target gene products AM and VEGF are elevated in CC-RCC compared with other renal tumour types, but plasma AM is not a specific marker for CC-RCC.
